Galmed Announces Grant of Patent for Combination of Aramchol with Resmetirom
TEL AVIV, Israel, May 4, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) reported today the execution of a definitive agreement for a $3M equity investment in OnKai Inc., leading an investment round of $6M. The agreement provides Galmed with a minority, but a strategic stake in Onkai. Concurrently, a strategic partnership agreement is being signed to advance both companies by leveraging their complementary knowledge and experience in their respective fields.